Compare AVTX & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVTX | MCHX |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 71.6M |
| IPO Year | 2015 | 2004 |
| Metric | AVTX | MCHX |
|---|---|---|
| Price | $18.08 | $1.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $32.29 | N/A |
| AVG Volume (30 Days) | ★ 325.7K | 20.6K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $192,000.00 | ★ $46,494,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.39 | $1.26 |
| 52 Week High | $20.72 | $2.31 |
| Indicator | AVTX | MCHX |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 48.44 |
| Support Level | $18.58 | $1.61 |
| Resistance Level | $19.97 | $1.69 |
| Average True Range (ATR) | 1.29 | 0.07 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 27.60 | 33.36 |
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Marchex Inc harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales, and marketing teams to optimize customer journey experiences across communications channels, enabling enterprise strategies, empowering businesses to increase revenue through informed decision-making and strategic execution.